21 Jan 2014 07:00
21 January, 2014
BIOQUELL PLC
Appointment of Michael Roller as Group Finance Director
Bioquell PLC ("Bioquell") (LSE symbol: BQE) - provider of specialist microbiological control technologies to the international Healthcare, Life Sciences & Defence markets; and specialist testing services in the UK via its TRaC division, today announces that it has appointed Michael Roller (ACA) to be its new Group Finance Director.
Mr Roller has previously been Finance Director of a number of quoted companies, most recently Corin Group plc, has significant experience within the Life Sciences sector and is a non-executive director of Filtronic plc. He has also held a number of other senior finance roles in a broad range of listed and private companies. He qualified as an accountant with KPMG. No other information is required to be disclosed pursuant to Listing Rule 9.6.13R in relation to Mr Roller's appointment as a director of the Company.
Michael Roller will start work with the Group on 10 February 2014 and will formally assume the role of Group Finance Director on 18 March, following the announcement of the Group's preliminary results for the year ended 31 December 2013.
Commenting on the recruitment of Michael Roller as Group Finance Director, Nigel Keen, Bioquell's Chairman, said:
"We are delighted that Michael has agreed to join Bioquell as Finance Director. He has extensive and highly relevant experience - and we look forward to his contribution to the next stage in the growth of the Group."
- Ends -
Enquiries:
Bioquell PLC 01264 835 900
Nigel Keen Chairman
Nick Adams Group Chief Executive
*******************
Notes to editors:
§ The Group is a UK-headquartered, international technology company with two divisions:
o Bioquell (www.bioquell.com) which sells specialist bio-contamination control products and services into the Healthcare, Life Sciences and Defence sectors, with most of its revenues generated from overseas customers; and
o TRaC (www.tracglobal.com) which provides specialist Testing, Regulatory and Compliance services - including EMC, environmental and safety testing - principally to UK corporates.
§ Bioquell's bio-contamination control technology is principally based around hydrogen peroxide vapour ("HPV") - which is highly efficacious at eradicating micro-organisms such as bacteria and viruses at room temperature - and is subsequently broken down using specialist catalysts to water vapour and oxygen (hence an extremely 'green' technology) at the end of the bio-decontamination process.
§ For the last three years Bioquell has invested substantial sums in developing a new product range which has been designed to increase the proportion of recurring revenues from its HPV technology - and hence increase its quality of earnings.
§ Bioquell's bio-contamination control technology:
o is used by bio-pharmaceutical, biotechnology and research institutions to provide sterile equipment and/or sterile working environments;
o is used to eradicate "superbugs" from hospitals; independent scientific research has demonstrated that 'bioquelling' hospital equipment and facilities reduces significantly the rates of hospital acquired infection;
o is used to provide single rooms to hospitals (via the ICE-pod) which currently only have open, multi-bed "Nightingale" ward structures
o has been incorporated in a wound-care product - BioxyQuell - which has received regulatory approval for use on chronic wounds in the European Union; and
§ Bioquell currently has overseas operations in the USA, France, Ireland, Singapore, China and Brazil.
TRaC sells its specialist services to the product development departments of a broad range of companies, principally based in the UK, with a particular focus on organisations operating in the aerospace and defence sectors.